All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse events (TEAEs) related to GPRC5D targeting, including those affecting the oral cavity, skin, and nails, were Grade 1–2, with two patients experiencing Grade 3 rash. Among patients treated at doses ≥120 μ...
All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse events (TEAEs) related to GPRC5D targeting, including those affecting the oral cavity, skin, and nails, were Grade 1–2, with two patients experiencing Grade 3 rash. Among patients treated at doses ≥120 μg/kg (n=24), the overall response rate (ORR) was 83.3%, including 4 stringent complete responses (sCR), 7 very good partial responses (VGPR), and 9 partial responses (PR). In this cohort, the ORR was 80% among 10 patients with extramedullary disease (EMD) and 77.8% among 9 patients previously treated with BCMA- and/or GPRC5D-directed therapies. Among patients who achieved complete response or better, the minimal residual disease (MRD) negativity rate was 100% (n=4), as assessed by validated next generation sequencing, with a threshold of 10 -5 , performed at a central laboratory. Thirty-nine patients with R/R MM who had previously received at least a PI, an IMiD, and an anti-CD38 monoclonal antibody were treated with IBI3003 at dose levels ranging from 0.1 μg/kg to 800 μg/kg and underwent at least one tumor assessment after baseline. As of the data cutoff date of November 7, 2025, the median follow-up duration was 3.25 months (range: 0.4–7.4), and the median treatment duration was 12.14 weeks (range: 1.0–33.0). Clinical data presented at the American Society of Hematology (ASH) Annual Meeting on December 7, 2025[ Link ], demonstrated a tolerable safety profile and promising efficacy signals for IBI3003 in patients who had failed ≥2 prior lines of myeloma therapy: IBI3003 was discovered and developed using Innovent's proprietary Sanbody® platform and its development is being advanced globally. IBI3003 is currently undergoing a Phase 1/2 clinical trial in patients with relapsed or refractory multiple myeloma in China and Australia, and there are plans to initiate a Phase 1/2 ...
Explore the exciting world of Cadence Design Systems (NASDAQ: CDNS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Dec. 10, 2025. The video was published on Jan. 26, 2026. Continue reading
Explore the exciting world of Cadence Design Systems (NASDAQ: CDNS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Dec. 10, 2025. The video was published on Jan. 26, 2026. Continue reading
China’s struggling solar sector faces fresh turbulence as the planned removal of a key export-tax rebate threatens to disrupt demand patterns, according to Longi Green Energy Technology Co . The tax change — which is due to kick in from April 1 and is meant to promote industry consolidation — could leave manufacturers scrambling to ship orders ahead of the shift, followed by a sharp drop-off once ...
China’s struggling solar sector faces fresh turbulence as the planned removal of a key export-tax rebate threatens to disrupt demand patterns, according to Longi Green Energy Technology Co . The tax change — which is due to kick in from April 1 and is meant to promote industry consolidation — could leave manufacturers scrambling to ship orders ahead of the shift, followed by a sharp drop-off once the rebate is withdrawn, Vice President Zhang Haimeng said in an interview. To cope with the near-term rush, companies may ask staff to work overtime during the upcoming Chinese New Year holiday, Zhang said. The potential upheaval risks adding to the mounting challenges faced by Chinese solar manufacturers. The sector has reported deep losses over the past two years due to persistent oversupply, and is now also facing lower margins as the price of key input silver soars to record highs. While the removal of the rebates on solar products has long been under consideration, the demand surge won’t be sustained, according to Zhang, who spoke on the sidelines of the World Economic Forum in Davos, Switzerland. “This is similar to the first quarter of last year,” said Zhang, referring to an earlier policy shift in renewable-power pricing. “That policy change resulted in a spike in demand, and then the demand came off quite a bit after that. My worry is the same thing may happen again.” On the challenge posed by soaring silver prices, Longi and several domestic peers have announced a push to reduce usage of the precious metal in their products. A specific plan is still being finalized, according to Zhang. “The technology is not fully commercialized,” Zhang said last week. “We’ll have more visibility in a few months in terms of the performance of the technology at scale, and the cost advantage.” Longi has also expanded into energy storage to seek a new growth engine, in addition to its solar business. The company is currently in a market-testing phase, with Europe seen as a likely pr...
Us stock futures were a mixed bag Monday evening as Wall Street headed into a packed earnings week and investors look ahead to the Federal Reserve’s upcoming interest rate decision. Futures tied to the Dow Jones Industrial Average (YM=F) fell around 0.3%, amid a sharp decline from UnitedHealth (UNH). S&P 500 futures (ES=F) hovered just below the flatline, while Nasdaq 100 futures (NQ=F) inched up ...
Us stock futures were a mixed bag Monday evening as Wall Street headed into a packed earnings week and investors look ahead to the Federal Reserve’s upcoming interest rate decision. Futures tied to the Dow Jones Industrial Average (YM=F) fell around 0.3%, amid a sharp decline from UnitedHealth (UNH). S&P 500 futures (ES=F) hovered just below the flatline, while Nasdaq 100 futures (NQ=F) inched up 0.1%. During Monday’s regular session, stocks moved higher to start the week, supported by gains in major technology names. Shares of Apple (AAPL), Meta Platforms (META), and Microsoft (MSFT) advanced ahead of their earnings reports later this week. Earnings season ramps up significantly in the days ahead, with more than 90 S&P 500 companies scheduled to report. That slate includes several members of the so-called "Magnificent Seven," with Meta, Microsoft, and Tesla (TSLA) set to release results on Wednesday, followed by Apple on Thursday. Investors are also bracing for the Federal Reserve’s first policy decision of the year. While the Fed is widely expected to hold its benchmark rate steady in a range of 3.5% to 3.75%, traders will be watching closely for signals on the timing of future rate cuts. Meanwhile, investors are grappling with new risks from Washington. President Trump said late Monday that tariffs on South Korean products — including autos, pharmaceuticals, and lumber — would be raised to 25% from 15%. Trump cited delays in South Korea’s legislature approving a trade agreement reached with the US last summer. A government shutdown is also looming as Senate Democrats are attempting to block a bill funding the Department of Homeland Security following federal agents killing Alex Pretti, an American citizen, in Minneapolis. On the economic calendar, Tuesday brings updated readings on consumer confidence and home prices. Corporate earnings due Tuesday include results from General Motors (GM), American Airlines (AAL) and Boeing (BA). Elsewhere in corporates, UnitedHe...
Us stock futures climbed Tuesday morning as Wall Street headed into a packed earnings week and investors look ahead to the Federal Reserve’s upcoming interest rate decision. Futures tied to the Dow Jones Industrial Average (YM=F) hovered around the baseline. S&P 500 futures (ES=F) rose 0.4%, while Nasdaq 100 futures (NQ=F) climbed 0.7%. During Monday’s regular session, stocks moved higher to start...
Us stock futures climbed Tuesday morning as Wall Street headed into a packed earnings week and investors look ahead to the Federal Reserve’s upcoming interest rate decision. Futures tied to the Dow Jones Industrial Average (YM=F) hovered around the baseline. S&P 500 futures (ES=F) rose 0.4%, while Nasdaq 100 futures (NQ=F) climbed 0.7%. During Monday’s regular session, stocks moved higher to start the week, supported by gains in major technology names. Shares of Apple (AAPL), Meta Platforms (META), and Microsoft (MSFT) advanced ahead of their earnings reports later this week. Earnings season ramps up significantly in the days ahead, with more than 90 S&P 500 companies scheduled to report. That slate includes several members of the so-called "Magnificent Seven," with Meta, Microsoft, and Tesla (TSLA) set to release results on Wednesday, followed by Apple on Thursday. Investors are also bracing for the Federal Reserve’s first policy decision of the year. While the Fed is widely expected to hold its benchmark rate steady in a range of 3.5% to 3.75%, traders will be watching closely for signals on the timing of future rate cuts. Meanwhile, investors are grappling with new risks from Washington. President Trump said late Monday that tariffs on South Korean products — including autos, pharmaceuticals, and lumber — would be raised to 25% from 15%. Trump cited delays in South Korea’s legislature approving a trade agreement reached with the US last summer. A government shutdown is also looming as Senate Democrats are attempting to block a bill funding the Department of Homeland Security following federal agents killing Alex Pretti, an American citizen, in Minneapolis. On the economic calendar, Tuesday brings updated readings on consumer confidence and home prices. Corporate earnings due Tuesday include results from General Motors (GM), American Airlines (AAL) and Boeing (BA). Elsewhere in corporates, UnitedHealth shares and other insurer stocks sank after a report said the U...
US stock futures moved higher on Tuesday as a packed earnings week continued and investors looked ahead to the Federal Reserve’s upcoming interest rate decision. Contracts on the S&P 500 (ES=F) rose 0.3%, while those on the tech-heavy Nasdaq 100 (NQ=F) advanced 0.6%. Dow Jones Industrial Average futures (YM=F) were little changed on the heels of gains for Wall Street indexes. Earnings due Tuesday ...
US stock futures moved higher on Tuesday as a packed earnings week continued and investors looked ahead to the Federal Reserve’s upcoming interest rate decision. Contracts on the S&P 500 (ES=F) rose 0.3%, while those on the tech-heavy Nasdaq 100 (NQ=F) advanced 0.6%. Dow Jones Industrial Average futures (YM=F) were little changed on the heels of gains for Wall Street indexes. Earnings due Tuesday include results from General Motors (GM), American Airlines (AAL) and Boeing (BA). Elsewhere in corporates, UnitedHealth shares and other insurer stocks sank after a report said the Trump administration plans to keep Medicare payments to insurers roughly steady next year. Earnings season ramps up significantly in the days ahead, with more than 90 S&P 500 companies scheduled to report. That slate includes several members of the so-called "Magnificent Seven," with Meta (META), Microsoft (MSFT), and Tesla (TSLA) set to release results on Wednesday, followed by Apple (AAPL) on Thursday. Later, the Federal Reserve begins its two-day meeting, which will bring its first policy decision of the year. While policymakers are widely expected to hold the benchmark interest rate steady on Wednesday, traders will be watching closely for signals on the timing of future rate cuts. Updated readings on consumer confidence and home prices due later Tuesday offer insight into the economy ahead of the call. Meanwhile, investors are grappling with new risks from Washington. President Trump said late Monday that tariffs on South Korean products — including autos, pharmaceuticals, and lumber — will be raised to 25% from 15%. Trump cited delays in South Korea’s legislature approving a trade agreement reached with the US last summer. A government shutdown is also looming as Senate Democrats attempt to block a bill funding the Department of Homeland Security. The political pushback follows federal agents killing Alex Pretti, an American citizen, in Minneapolis. LIVE 2 updates
距离“迄今最薄iPhone”上市仅三个月，iPhone Air 就以一种意想不到的方式再次成为了焦点——只是这一次，是因为价格大“跳水”。 1月23日，苹果发布新春限时优惠活动。在苹果天猫官方旗舰店内，这款2025年10月22日才正式发售，厚度仅有5.6毫米、重165克的iPhone Air，官方立减2000元，叠加部分地区国补后，到手价仅5499元起。 图/天猫“Apple Store 官方旗舰...
(RTTNews) - Five Star Bancorp (FSBC) announced a profit for its fourth quarter that Increased, from last year and beat the Street estimates. The company's bottom line came in at $17.64 million, or $0.83 per share. This compares with $13.32 million, or $0.63 per share, last year. Analysts on average had expected the company to earn $0.76 per share. Analysts' estimates typically exclude special item...
(RTTNews) - Five Star Bancorp (FSBC) announced a profit for its fourth quarter that Increased, from last year and beat the Street estimates. The company's bottom line came in at $17.64 million, or $0.83 per share. This compares with $13.32 million, or $0.63 per share, last year. Analysts on average had expected the company to earn $0.76 per share. Analysts' estimates typically exclude special items. The company's revenue for the period rose 23.7% to $43.49 million from $35.16 million last year. Five Star Bancorp earnings at a glance (GAAP) : -Earnings: $17.64 Mln. vs. $13.32 Mln. last year. -EPS: $0.83 vs. $0.63 last year. -Revenue: $43.49 Mln vs. $35.16 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Aerial view of Seoul downtown city skyline with vehicle on expressway and bridge cross over Han river in Seoul city, South Korea. Mongkol Chuewong | Moment | Getty Images Asia-Pacific markets were set to open mixed Tuesday, after U.S. President Donald Trump took aim at South Korea overnight, threatening to increase tariffs on Asia's fourth-largest economy. Trump said on Truth Social that the count...
Aerial view of Seoul downtown city skyline with vehicle on expressway and bridge cross over Han river in Seoul city, South Korea. Mongkol Chuewong | Moment | Getty Images Asia-Pacific markets were set to open mixed Tuesday, after U.S. President Donald Trump took aim at South Korea overnight, threatening to increase tariffs on Asia's fourth-largest economy. Trump said on Truth Social that the country's legislature has not approved Seoul's trade deal with Washington, and that tariffs on the South Korea will climb to 25%, from 15%. The threat could dent sentiment in South Korean markets, which has notched 15 days of gains out of the 17 sessions since the start of the year. Australia's S&P/ASX 200 started the day 1.12% up, reaching its highest level in almost 3 months, coming back from a holiday on Monday. Japan's Nikkei 225 futures pointed to a weaker open for the market, with the futures contract in Chicago at 52,880, and its counterpart in Osaka at 52,790, compared to the previous close of 52,885.25. Hong Kong Hang Seng index futures were at 26,883, higher than the HSI's last close of 26,765.52. Overnight in the U.S., the S&P 500 index advanced 0.50%, while the Dow Jones Industrial Average gained 0.64%. The Nasdaq Composite climbed 0.43%, supported by jumps of about 3%, 2% and 1% in Apple , Meta Platforms and Microsoft , respectively, ahead of their earnings reports later in the week. —CNBC's Sean Conlon and Fred Imbert contributed to this report.
在刚刚过去的周末四十八小时，如果你还沉浸在 Claude Code 的各种 Skill 技能中，那你有可能意外地错过了一个现象级的爆款 AI Agent 产品——Clawdbot，无数海外 AI 博主将其称为： 「迄今为止最伟大的 AI 应用」 。 Clawdbot 确实能称得上现象级产品。无数友商大佬纷纷安利，甚至为了它专门购买 Mac mini，其中甚至包括 Google AI Studio ...
在刚刚过去的周末四十八小时，如果你还沉浸在 Claude Code 的各种 Skill 技能中，那你有可能意外地错过了一个现象级的爆款 AI Agent 产品——Clawdbot，无数海外 AI 博主将其称为： 「迄今为止最伟大的 AI 应用」 。 Clawdbot 确实能称得上现象级产品。无数友商大佬纷纷安利，甚至为了它专门购买 Mac mini，其中甚至包括 Google AI Studio 的产品负责人。这款 Clawdbot 从爆火开始，就与 Mac mini 这个硬件高度绑定，成为一套出圈组合。 能让 Google AI Studio 产品负责人主动「安利」苹果产品，Clawdbot 魅力可见一斑｜图片来源：X 但不要误会，这篇文章并不是想向你安利这款产品。恰恰相反，是想帮你缓解一些焦虑：你并没有错过什么， 因为现阶段 Clawdbot还只是一个「极客玩具」 。 01 Clawdbot 是什么？ Clawdbot 是一个开源的本地 AI 智能体项目，Peter Steinberger 和社区一起做的，吉祥物是只龙虾。 相比于以往的本地开源 AI 项目，Clawdbot 做了两件事： 一是给你一套「能动手」的工具 ——浏览器控制、Shell、文件读写、定时任务、画布什么的——让模型的输出能直接变成动作。 二是做了个网关 ，把 WhatsApp、Slack、Discord、Signal、iMessage、Teams 这些聊天渠道接进来。你用任何一个熟悉的聊天窗口，都能远程指挥你的电脑。 用对话的方式高权限地控制一台设备，帮你完成几乎所有任务，是 Clawdbot 的主要卖点｜图片来源：X Clawdbot 的概念其实并不复杂，但真正关键的需求反而在硬件上：它需要一个地方 7×24 小时运行它能跑在 macOS、Linux 和 Windows（通过 WSL2）上。核心想法很简单：配置和记忆都留在你自己的硬盘，模型调用在需要推理的时候发生。 说白了就是「电脑上常驻的 AI 代理 + 聊天入口的总机」。这也解释了它为什么突然刷屏：大家脑子里的贾维斯幻想，变成了一个能下载、能跑、能折腾的东西。 02 它能做什么？ 笔者也在周末实际体验了一下 Clawdbot，在相对简单的安装过后，真正复杂的环节是如何配置它，让 Clawdbot 变得适合你自己的需求；同时 Clawd...